Latest Private Equity Funds News

CD Private Equity Fund I (ASX:CD1) posted a net loss of $6.96 million for the year ended 31 March 2026, driven by a $5.14 million fair value decline in its US private equity holdings and significant foreign exchange pressures. Despite near-term setbacks, the Fund has delivered an 8.3% post-tax annual return since inception.

CD Private Equity Fund III (ASX:CD3) posted a net loss of $9.01 million for FY26, weighed down by foreign exchange losses and fair value declines. Despite near-term challenges, the Fund sustains strong long-term performance and liquidity.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

HMC Capital has unveiled a streamlined strategy focusing on high-return platforms across real estate, digital infrastructure, private credit, and energy transition, reaffirming its FY26 operating EPS guidance above 40 cents pre-tax and announcing significant capital recycling and growth initiatives.

Australian Vanadium Limited has raised $7.5 million through a targeted placement to accelerate its vertically integrated vanadium strategy, including the Kalgoorlie battery energy storage project.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

360 Capital REIT reported a 63.2% rise in statutory profit to $3.1 million for H1 2026, maintaining distributions and expanding its portfolio with a $10 million Sydney apartment block investment.

The CD Private Equity Fund Series reported robust performance in 2025, with improved exit activity and solid distributions despite currency headwinds. The funds continue to focus on asset-by-asset realisations while exploring portfolio liquidity options.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.

Australian Vanadium Limited has made significant strides in its integrated vanadium project, advancing its feasibility study and securing key environmental approvals while preparing to bid for a major Western Australian battery storage project.

CD Private Equity Fund II announces a $0.38 per unit distribution reflecting recent portfolio realisations, delivering nearly double the initial investment in returns since inception.